Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7055MR)

This product GTTS-WQ7055MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7055MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7475MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ15442MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ2450MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ8075MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ13575MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ2902MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ12479MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ8334MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW